Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 13, 2014, Pages 3564-3571

  Dhaneshwar, Suneela S ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

2; 4; 4 Aminosalicylic acid; 5 Aminosalicylic acid; 6 trinitrobenzene sulphonic acid; Colon specific prodrug; Experimental colitis; Inflammatory bowel disease; Sulfasalazine; Ulcerative colitis

Indexed keywords

2 NITROPHENOL; 3 NITROPHENOL; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AMIDE PRODRUG; AMINOSALICYLGLYCINE; AMINOSALICYLIC ACID; AMMONIUM CHLORIDE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ARGININE; BALSALAZIDE; CHLOROPHENOL; COLON SPECIFIC PRODRUG; CORTICOSTEROID; DIGOXIN; GLYCINE; IMMUNOMODULATING AGENT; INFLIXIMAB; ISONIAZID; MESALAZINE; OLSALAZINE; PROBENECID; PROBIOTIC AGENT; PRODRUG; RECOMBINANT ANTIINFLAMMATORY CYTOKINE; SALAZOSULFAPYRIDINE; SALICYLAMIDE; SALICYLIC ACID; SALICYLURIC ACID; SULFAPYRIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMINOSALICYLIC ACID DERIVATIVE; IPSALAZIDE; LOW MOLECULAR WEIGHT HEPARIN; OMEGA 3 FATTY ACID; PHENYLHYDRAZINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); COLON; CROHN DISEASE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; HUMAN; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PREGNANCY; ULCERATIVE COLITIS; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES;

AMINOSALICYLIC ACID; AMINOSALICYLIC ACIDS; CLINICAL TRIALS AS TOPIC; COLON; FATTY ACIDS, OMEGA-3; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; PHENYLHYDRAZINES; PRODRUGS; SULFASALAZINE;

EID: 84897475565     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i13.3564     Document Type: Article

References (53)

1. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997; 273: G769-G775 [PMID: 9357817]
2. Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011; 27: 346-357 [PMID: 21654383]
3. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; (1): CD004115 [PMID: 20091560 DOI: 10.1002/14651858. CD004115.pub2]
4. Van Bodegraven AA, Wijmenga C. Inflammatory bowel disease. Genomic and personalized medicine. In: Willard GH, Ginsburg W, editors. Bethesda: Elsevier, 2009: 1040-1055 [DOI: 10.1016/B978-0-12-369420-1.00086-X]
5. Crohn's and colitis foundation of America, Inc. 1996-2002. Available from: URL: http://www.ccfa.org/physician/colitisb.html
6. National digestive diseases information clearinghouse, 2 information way Bethesda, MD: 2893-3570. Available from: URL: http://www.niddk.nih.gov/health/digest/pubs/colitis/colitis.htm. Accessed on 08/10/2008
7. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007; 42: 16-25 [PMID: 17322989 DOI: 10.1007/s00535-006-1995-7]
8. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des 2014; 20: 1082-1096 [PMID: 23782147]
9. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657 [PMID: 17499606 DOI: 10.1016/ S0140-6736(07)60751-X]
10. Di Paolo MC, Paoluzi OA, Pica R, Iacopini F, Crispino P, Rivera M, Spera G, Paoluzi P. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Dig Liver Dis 2001; 33: 563-569 [PMID: 11816545 DOI: 10.1016/S1590-8658(01)80108-0]
11. Sulfasalazine. Available from: URL: http://www.drugs. com/mtm/sulfasalazine.html. Accessed on 9th Aug 2013
12. Dhaneshwar SS, Chail M, Patil M, Naqvi S, Vadnerkar G. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur J Med Chem 2009; 44: 131-142 [PMID: 18472188 DOI: 10.1016/j.ejmech.2008.03.035]
13. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539 [PMID: 12235076 DOI: 10.1136/gut.51.4.536]
14. Decocq G, Gras-Champel V, Vrolant-Mille C, Delcenserie R, Sauvé L, Masson H, Andréjak M. Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature. Therapie 1999; 54: 41-48 [PMID: 10216421]
15. Marteau P, Halphen M. [Comparative randomized open study of the efficacy and tolerance of enemas with 2 gr of 4-amino-salicylic acid (4-ASA) and 1 gr of 5-amino-salicylic acid (5-ASA) in distal forms of hemorrhagic rectocolitis]. Gastroenterol Clin Biol 1995; 19: 31-35 [PMID: 7720988]
16. Beeken W, Howard D, Bigelow J, Trainer T, Roy M, Thayer W, Wild G. Controlled trial of 4-ASA in ulcerative colitis. Dig Dis Sci 1997; 42: 354-358 [PMID: 9052519]
17. Ginsberg AL, Davis ND, Nochomovitz LE. Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid. Gastroenterology 1992; 102: 448-452 [PMID: 1290475]
18. Schreiber S, Howaldt S, Raedler A. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. Gut 1994; 35: 1081-1085 [PMID: 7926910 DOI: 10.1136/gut.35.8.1081]
19. Mitchell SC, Waring RH. Aminophenols. In: Ullmann's Encyclopedia of Industrial Chemistry. Wiley-VCH Verlag GmbH & Co, KGaA. Weinheim: Wiley-VCH, 2000: 5-29 [DOI: 10.1002/14356007.a02_099]
20. Lover MJ, inventor. Block Drug Company, Inc, Jersey City, NJ, assignee. Use of 4-aminosalicylic acid as an anti-inflammatory agent. US patent. 44 40 763. 1984 Apr 3
21. Campieri M, Lanfranchi GA, Bertoni F, Brignola C, Bazzocchi G, Minguzzi MR, Labò G. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 1984; 29: 204-208 [PMID: 6381184 DOI: 10.1159/000199034]
22. Daniel F, Seksik P, Cacheux W, Jian R, Marteau P. Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. Inflamm Bowel Dis 2004; 10: 258-260 [PMID: 15290921 DOI: 10.1097/00054725-200405000-00013]
23. O'Donnell LJ, Arvind AS, Hoang P, Cameron D, Talbot IC, Jewell DP, Lennard-Jones JE, Farthing MJ. Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. Gut 1992; 33: 947-949 [PMID: 1644335 DOI: 10.1136/gut.33.7.947]
24. Selby WS, Bennett MK, Jewell DP. Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas. Digestion 1984; 29: 231-234 [PMID: 6381186 DOI: 10.1159/000199038]
25. Ahnfelt-Rønne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98: 1162-1169 [PMID: 1969825]
26. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28: 190-195 [PMID: 2881849 DOI: 10.1136/gut.28.2.190]
27. Williams JG, Hallett MB. Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils. Gut 1989; 30: 1581-1587 [PMID: 2574700 DOI: 10.1136/gut.30.11.1581]
28. Nielsen OH, Ahnfelt-Rønne I. 4-Aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl. Pharmacol Toxicol 1988; 62: 223-226 [PMID: 3133649 DOI: 10.1111/j.1600-0773.1988. tb01876.x]
29. Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich MJ, Nash GS. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991; 101: 1020-1030 [PMID: 1889695]
30. Schreiber S, Raedler A, Stenson WF, MacDermott RP. The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am 1992; 21: 451-502 [PMID: 1512051]
31. von Ritter C, Grisham MB, Granger DN. Sulfasalazine metabolites and dapsone attenuate formyl-methionyl-leucylphenylalanine- induced mucosal injury in rat ileum. Gastroenterology 1989; 96: 811-816 [PMID: 2563347]
32. Schless JM, Inglis RM, Hammond JH, Hale JM. Comparative evaluation of blood levels and tolerance of sodium PAS and conjugated PAS and ascorbic acid. Dis Chest 1966; 50: 595-600 [PMID: 5964864 DOI: 10.1378/chest.50.6.595]
33. Cannemeyer W, Thompson JR, Lichtenstein MR. Severe paraaminosalicylic acid hypersensitivity; blood and lymph node studies. Blood 1955; 10: 62-75 [PMID: 13219189]
34. Gisbert JP, Gomollón F, Maté J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002; 47: 471-488 [PMID: 11911332]
35. McEvoy GK. Aminosalicylic acid. AHFS Drug Information 2007. US: American Society of Health-System Pharmacists, 2007: 544-546
36. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414), to June 28, 1996. MD: Rockville, 1996
37. Aminosalicylic Acid. Available from: URL: http://www.drugs.com/monograph/aminosalicylic-acid.html. Accessed on 23rd Sep 2013
38. Drug information. Available from: URL: http://www.ahfsdruginformation.com. Accessed on 28th July 2013
39. Nagy F, Karacsony G, Varro V. Experience with topical administration of 4-aminosalicylic acid in ulcerative colitis. Dis Colon Rectum 1989; 32: 134-137 [PMID: 2563344 DOI: 10.1007/BF02553826]
40. Mital OP, Singh G, Raj B. Case report of fatal reaction to paraaminosalicylic acid and streptomycin. Ind J Tub 1991; 2: 72-73
41. Zhao ZB, Guo J, Wei YG, Liang TD. Synthesis of 4-aminosalicylglycine. Chinese Chem Lett 2005; 16: 889-892
42. Wallace JL, Cirino G, Sparatore A, inventors. Antibe Therapeutics Inc, Calgary, CA, Assignee. Salts of 4- or 5-aminosalicylic acid. US patent. 20060003972A1. 2006 Jan 5
43. Akisu M, Ozmen D, Baka M, Habif S, Yalaz M, Arslanoglu S, Kultursay N, Bayindir O. Protective effect of dietary supplementation with L-arginine and L-carnitine on hypoxia/reoxygenation-induced necrotizing enterocolitis in young mice. Biol Neonate 2002; 81: 260-265 [PMID: 12011570 DOI: 10.1159/000056757]
44. Shah PS, Shah VS. Arginine supplementation for prevention of necrotising enterocolitis in preterm infants. Cochrane Database of Sys Rev 2007; (3): CD004339 [PMID:17636753]
45. Wallace JL, Cirino G, Caheno G, Sparatore A, Santagada V, Fiorucci S, inventors. Derivatives of 4- and 5-aminosalicylic acids. US patent. 20060270635A1. 2006 Nov 30
46. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Antonelli E, Roviezzo F, Morelli A, Cirino G, Wallace JL, Fiorucci S. Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther 2006; 316: 325-335 [PMID: 16192316 DOI: 10.1124/jpet.105.091595]
47. Zhao ZB, Zheng HX, Wei YG, Liu J. Synthesis of azo derivatives of 4-aminosalicylic acid. Chinese Chem Lett 2007; 18: 639-642 [DOI: 10.1016/j.cclet.2007.04.031]
48. Almenier HA, Al Menshawy HH, Maher MM, Al Gamal S. Oxidative stress and inflammatory bowel disease. Front Biosci (Elite Ed) 2012; 4: 1335-1344 [PMID: 22201958 DOI: 10.2741/463]
49. Sheng SF, Zheng HX, Liu J, Zhao ZB. Synthesis of phenolclass azo derivatives of 4-aminosalicylic acid. Chinese Chem Lett 2008; 19: 419-422 [DOI: 10.1016/j.cclet.2008.01.042]
50. Dhaneshwar SS, Sharma M, Vadnerkar G. Co-drugs of aminosalicylates and nutraceutical amino sugar for ulcerative colitis. J Drug Del Sci Tech 2011; 21: 527-533
51. Yadav R, Mahatma OP, Singhvi I. Preparation and evaluation of polymeric prodrug of 4-aminoslicylic acid: colonic drug delivery in inflammatory bowel disease. IJPI's J Pharmaceut Cosmetol 2011; 1: 1-9
52. Vadnerkar G, Dhaneshwar S. Macromolecular prodrug of 4-aminosalicylic acid for targeted delivery to inflamed colon. Curr Drug Discov Technol 2013; 10: 16-24 [PMID: 22725691 DOI: 10.2174/1570163811310010004]
53. Suneela D, Gaurav V, Himanshu R. Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach. Inflamm Allergy Drug Targets 2013; 12: 328-340 [PMID: 24001333 DOI: 10.2174/18715281113129990059]